Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Dasatinib Drugs Market Size Shifted, And What Is the Outlook Through 2034?
The market for dasatinib drugs has witnessed robust growth in the recent years. The market which was valued at $1.45 billion in 2024, is predicted to expand to $1.55 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The historic growth can be tracked back to a surge in the cases of chronic myeloid leukemia (CML), an increase in specified cancer treatments, enhancement in research on tyrosine kinase inhibitors (TKIS), an elevation in funding for cancer research, and a growth in the number of clinical trials.
How Much Will the Dasatinib Drugs Market Be Worth in 2029?
A surge in the market size of dasatinib drugs is anticipated over the coming years, with projections indicating an expansion up to $2 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is attributed to several factors, including accelerated investments in oncology drug pipelines, a rise in drug-resistant leukemia cases, increased availability of generic versions of dasatinib, an intensified focus on reducing chemotherapy side effects, as well as improved awareness and early detection of leukemia. The period also expects to witness trending developments including the adoption of personalized medicine, the application of companion diagnostics, the creation of new drug formulations, advances in combination therapies, and the launch of biosimilars.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19023&type=smp
Which is the Largest Company in the Dasatinib Drugs Market?
Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP
What Are the Main Market Drivers in the Dasatinib Drugs Industry?
The escalating incidence of chronic myeloid leukemia (CML), a cancer that impacts the bone marrow and blood through abnormal white blood cell growth, is anticipated to fuel the expansion of the dasatinib drug market in the future. Factors such as changes in lifestyle demographics, poor diet, and escalating environmental risks largely influence the increasing prevalence of chronic myeloid leukemia (CML). Dasatinib medications effectively manage chronic myeloid leukemia (CML) by curbing the BCR-ABL (gene fusion) activity, a tyrosine kinase protein, birthed from the Philadelphia chromosome mutation which induces uncontrolled cancerous white blood cells’ proliferation. For instance, a report by the American Cancer Society (ACS), a US health organization aimed at eradicating cancer, in January 2023 established an increase in chronic myeloid leukemia (CML) cases to 8,930, up from 8,860 recorded in 2022 in the United States. Consequently, the proliferation of chronic myeloid leukemia (CML) is stimulating the dasatinib drug market’s growth.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=19023&type=smp
How Is the Dasatinib Drugs Market Segments Structured?
The dasatinib drugsmarket covered in this report is segmented –
1) By Product Type: Tablets, Oral Suspension, Other Products
2) By Indication: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Other Indications
3) By End User: Hospitals, Specialty Clinics, Home Healthcare
Subsegments:
1) By Tablets: 20 mg Tablets, 50 mg Tablets, 70 mg Tablets, 80 mg Tablets
2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension, 40 mg Or 5 mL Oral Suspension
3) By Other Products: Injectable Formulations, Combination Therapies, Generic Dasatinib Products
What Strategic Trends Are Transforming the Dasatinib Drugs Market?
Major companies operating in the dasatinib drugs market are focusing on developing generic drugs to expand their market share, provide cost-effective treatment options, and increase accessibility for patients. Generic medicines in the dasatinib market offer more affordable treatment options, improving patient access and promoting competition while reducing healthcare costs for patients. For instance, in September 2024, Apotex Corp., a Canada-based pharmaceutical company, launched the first generic version of Sprycel dasatinib in the United States to treat certain types of leukemia in adults and children. This cost-effective alternative improves access to high-quality treatment options. Its introduction marks a significant step in increasing competition and lowering prices in the dasatinib market.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/dasatinib-drugs-global-market-report
Which Global Regions Offer the Highest Growth in the Dasatinib Drugs Market?
North America was the largest region in the dasatinib drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19023
This Report Delivers Insight On:
1. How big is the dasatinib drugs market, and how is it changing globally?
2. Who are the major companies in the dasatinib drugs market, and how are they performing?
3. What are the key opportunities and risks in the dasatinib drugs market right now?
4. Which products or customer segments are growing the most in the dasatinib drugs market?
5. What factors are helping or slowing down the growth of the dasatinib drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model